查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1676874

儿童肺炎链球菌治疗市场按产品类型、年龄层、疾病类型、给药方式、治疗用途和最终用户划分 - 2025 年至 2030 年全球预测

Pediatrics Pneumococcal Therapeutics Market by Product, Age Group, Disease Type, Mode of Administration, Therapeutic Applications, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

儿童肺炎链球菌药物市场预计在 2024 年达到 121.8 亿美元，2025 年达到 131.5 亿美元，到 2030 年将达到 194.9 亿美元，复合年增长率为 8.14%。

主要市场统计数据
基准年 2024 年 121.8亿美元
预计 2025 年 131.5亿美元
预测年份 2030 194.9亿美元
复合年增长率（%） 8.14％

近年来，随着新的研究、先进的技术和对病原体动态的更深入的了解，儿童肺炎球菌治疗发生了重大变革时期。新治疗方法的开发不仅改善了临床结果，而且促进了加强儿童呼吸道感染疾病的预防策略。本介绍全面概况了当前的治疗状况，并概述了技术创新和资料驱动的见解在治疗儿童肺炎链球菌感染方面发挥的关键作用。

儘管长期以来一直推行疫苗接种和治疗方法，肺炎链球菌感染仍然是全世界儿童发病和死亡的主要原因之一。由于这种感染疾病负担继续挑战全球医疗保健系统，因此，重新定义一种将预防措施和先进的治疗性介入结合的方法至关重要。临床医生、研究人员和医疗保健政策制定者都致力于利用尖端科学和市场情报来制定有效、长期永续的解决方案。

由于儿科病原体的内在复杂性以及肺炎链球菌感染的多种临床表现，需要调整策略。本书以实证实践为重点，旨在揭示改变治疗格局的趋势、创新和策略市场变化，最终有助于改善患者的治疗效果并提高医疗管理的效率。该领域专注于切实可行的见解，从传统的治疗模式转变为以患者为中心的综合方法。

了解目前的研究和治疗状况可以帮助相关人员更好地认识到对抗儿童肺炎链球菌感染所做的多方面努力。随后的讨论包括对新兴趋势、竞争考察、区域动态和竞争环境的全面审查，所有这些都预示着儿科医疗保健的美好未来。

儿童肺炎链球菌药物的变革

近年来，由于生物技术的进步、不断发展的法律规范和新的临床指南，儿童肺炎球菌治疗方法发生了重大变化。治疗市场目前正在经历模式转移，重点从被动治疗感染疾病转向透过精准医疗和个人化免疫策略进行主动管理。

药物治疗的进步带来了超越传统抗生素治疗的创新浪潮。基于新机制的治疗方法，特别是识别和针对特定细菌毒力因子的治疗方法，已成为有希望的选择。同时，疫苗研发已成为全球对抗肺炎链球菌感染的核心。疫苗正变得越来越复杂，利用结合物和多醣製剂来扩大为儿童提供的免疫保护频谱。这种对治疗和预防的双重关注使我们能够更好地解决各种临床表现和病原体菌株所带来的复杂问题。

目前最大的变化之一涉及个人化医疗的整合。透过基因分析和生物标记识别，治疗可以更加个人化，减少抗生素抗药性和副作用的可能性，同时提高疫苗接种计划的有效性。向个人化治疗策略的转变不仅满足了个别患者的独特需求，而且符合旨在减轻感染疾病负担的全球医疗政策。

数位健康和​​高级分析进一步改变了临床决策。综合健康资讯系统使医疗保健专业人员能够即时监测患者治疗结果，快速调整治疗通讯协定，并更准确地追踪流行病学趋势。这些技术对改善治疗流程和确保儿科患者得到最适当和及时的护理做出了巨大贡献。

摘要，儿童肺炎球菌治疗的变革性转变的特点是创新药物开发、先进疫苗技术和数位健康解决方案的融合。总的来说，这些要素赋予了医疗保健提供者权力，有助于重组主动护理格局，优先考虑患者安全、提高疗效，并为患有肺炎链球菌感染的儿童提供适应性治疗方法。

深入了解儿童肺炎链球菌药物的关键领域

透过详细的細項分析可以准确了解儿童肺炎球菌治疗市场。可以从多个角度对这个市场进行分析，例如治疗产品的性质、年龄层、疾病类型、给药方式、在侵入性和非侵入性条件下的应用以及最终用户设定。

基于产品的细分区分药品和疫苗。在医药领域，传统药物疗法仍然是对抗感染疾病的关键，而疫苗领域则不断发展，并深度分类为结合疫苗和多醣体疫苗。每种疫苗都有不同的免疫抗原性原性，与传统疫苗相比，结合疫苗在幼儿身上能引发更强的免疫反应。

若以年龄层来考虑市场，婴幼儿是主要目标。这种区分至关重要，因为年轻族群的免疫成熟度和感染疾病易感性差异很大，需要製定个人化的治疗方法。

考虑到疾病类型，研究了细菌性肺炎、霉浆菌肺炎和病毒性肺炎的治疗市场。每种临床状况都需要其独特的治疗途径。细菌性肺炎通常进展更为严重，需要积极及时的干预，而霉浆菌和病毒性肺炎可能需要不同的治疗策略，包括支持性治疗和特定的抗病毒方案。

另一个重点是管理方法。有几种治疗选择，包括肌肉注射、鼻腔注射、静脉注射和口服。每种方法都有其优点和局限性，会影响药物输送速度和患者的依从性。同时，口服给药方便，支持门诊病人遵守治疗方案。

根据治疗应用，市场进一步细分为侵入性肺炎链球菌感染治疗和非侵入性肺炎链球菌感染治疗。前者包括菌血症和脑膜炎等严重，对于这些疾病，迅速而有力的干预至关重要。另一方面，中耳炎和鼻窦炎等非侵入性肺炎球菌疾病虽然不太严重，但需要精心治疗以防止併发症并改善生活品质。

实施治疗的环境也提供了一层分割。最终用户范围从诊所、医院到居家医疗，反映了提供儿科护理的多种环境以及影响获得护理机会的各种经济驱动因素。

综合起来，这些细分的见解揭示了一个多面向且充满活力的市场。了解这些方面将使相关人员能够针对儿科族群的特定需求，并确保治疗通讯协定不仅有效，而且还能适应临床和居家照护的现实环境。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 提高家长和医护人员对肺炎链球菌感染的认识
      • 合併疫苗使用增加导致儿童肺炎链球菌药物增加
      • 政府推动疫苗接种和预防性保健的措施和政策
    • 限制因素
      • 高昂的研发成本限制了新进者
    • 机会
      • 开发适合年龄的配方，以适应不同年龄的儿童
      • 投资远端医疗技术以扩大覆盖范围并改善患者治疗效果
    • 任务
      • 回应日益增长的伦理担忧和对儿童药物试验透明度的要求
  • 市场区隔分析
    • 产品：已证实对婴儿有效，从而推动结合疫苗的普及
    • 治疗应用：扩大儿童肺炎链球菌药物在侵袭性肺炎链球菌疾病的应用
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 儿童肺炎链球菌药物市场（依产品）

  • 药品
  • 疫苗
    • 结合疫苗
    • 多醣体疫苗

7. 儿童肺炎链球菌药物市场（依年龄层）

  • 婴儿
  • 婴儿

8. 儿童肺炎链球菌药物市场（依疾病类型）

  • 细菌性肺炎
  • 肺炎霉浆菌
  • 病毒性肺炎

9. 儿童肺炎链球菌药物市场（依给药方式）

  • 肌肉注射
  • 鼻腔内
  • 静脉
  • 口服

10. 儿童肺炎链球菌治疗市场-治疗应用

  • 侵袭性肺炎链球菌感染
    • 菌血症
    • 脑膜炎
  • 非侵袭性肺炎链球菌疾病
    • 中耳炎
    • 鼻窦炎

第 11 章儿童肺炎链球菌药物市场（按最终用户）

  • 诊所
  • 家庭护理设置
  • 医院

12. 美国儿童肺炎链球菌治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

13. 亚太地区儿童肺炎链球菌药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

14. 欧洲、中东和非洲儿童肺炎链球菌药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章 竞争格局

  • 2024 年市场占有率分析
  • FPNV 定位矩阵，2024 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Bharat Biotech International Limited
  • Biocon Limited
  • BioNTech SE
  • CanSino Biologics Inc.
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals
  • Hoffmann-La Roche AG
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novavax, Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila
Product Code: MRR-E336711C9EF2

The Pediatrics Pneumococcal Therapeutics Market was valued at USD 12.18 billion in 2024 and is projected to grow to USD 13.15 billion in 2025, with a CAGR of 8.14%, reaching USD 19.49 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 12.18 billion
Estimated Year [2025] USD 13.15 billion
Forecast Year [2030] USD 19.49 billion
CAGR (%) 8.14%

In recent years, pediatric pneumococcal therapeutics have undergone a significant transformation, driven by emerging research, advanced technologies, and a deeper understanding of pathogen dynamics. The development of novel therapeutic approaches has not only improved clinical outcomes but has also fostered enhanced preventive strategies against respiratory infections in children. This introduction provides a comprehensive overview of the current therapeutic environment, outlining the pivotal role of innovation and data-driven insights in addressing pneumococcal diseases in the pediatric population.

Pneumococcal infections remain one of the leading causes of childhood morbidity and mortality worldwide, despite longstanding vaccination and treatment regimens. As the burden of these infections continues to challenge healthcare systems globally, a redefined approach that integrates both preventive measures and advanced therapeutic interventions has become indispensable. Clinicians, researchers, and healthcare policymakers are all converging on the need to harness cutting-edge science and market intelligence to tailor solutions that are both effective and sustainable over time.

The necessity to adapt strategies arises from the inherent complexity of pediatric pathogens and the diverse clinical manifestations of pneumococcal diseases. With a focus on evidence-based practice, this narrative seeks to illuminate the trends, innovations, and strategic market shifts that are reshaping the therapeutic landscape, ultimately contributing to improved patient outcomes and more efficient healthcare management. Emphasis is placed on actionable insights as the sector pivots from traditional treatment paradigms in favor of integrated, patient-centric approaches.

By understanding the current state of research and therapy, stakeholders can better appreciate the multi-dimensional efforts underway to combat pneumococcal diseases in children. The discussions that follow comprise a thorough exploration of emerging trends, segmentation insights, regional dynamics, and the competitive environment, all of which signal a promising future for pediatric healthcare.

Transformative Shifts in Pediatric Pneumococcal Therapeutics

Recent years have witnessed transformative shifts in the approaches to pediatric pneumococcal therapeutics, driven by advancements in biotechnology, evolving regulatory frameworks, and novel clinical guidelines. The therapeutic market is now experiencing a paradigm shift as emphasis moves from reactive treatment of infections towards proactive management with precision medicines and tailored immunization strategies.

The evolution of drug therapies has brought a wave of innovation that extends beyond traditional antibiotic treatments. Newer, mechanism-based therapies, particularly those that identify and target specific bacterial virulence factors, have emerged as promising alternatives. In parallel, vaccine development has taken center stage in the global fight against pneumococcal diseases. Vaccines have become increasingly sophisticated, leveraging conjugate and polysaccharide formulations to broaden the spectrum of immune protection offered to children. This dual focus on both therapeutics and preventive measures ensures a robust response to the complexities presented by varying clinical presentations and pathogen strains.

One of the most significant changes in the landscape relates to the integration of personalized medicine. Through genetic profiling and biomarker identification, treatments are becoming more customized, reducing the likelihood of antibiotic resistance and adverse reactions, while enhancing the effectiveness of immunization schedules. The shift towards personalized treatment strategies not only caters to the unique needs of individual patients but also aligns with global healthcare policies aimed at reducing the burden of infectious diseases.

Digital health and advanced analytics have further transformed decision-making within clinical settings. Integrated health information systems allow practitioners to monitor patient outcomes in real time, adjust therapeutic protocols promptly, and track epidemiological trends more accurately. These technologies contribute significantly to refining treatment algorithms and ensuring that pediatric patients receive the most appropriate and timely care.

In summary, the transformative shifts in pediatric pneumococcal therapeutics are characterized by the convergence of innovative drug development, advanced vaccine technologies, and digital health solutions. These elements collectively empower healthcare providers, contributing to a reimagined and proactive therapeutic landscape that prioritizes patient safety, improved efficacy, and adaptive treatment modalities for children suffering from pneumococcal diseases.

Key Segmentation Insights in Pediatric Pneumococcal Therapeutics

A nuanced understanding of the pediatric pneumococcal therapeutics market is best achieved through detailed segmentation analysis. The market can be analyzed from several perspectives including the nature of the therapeutic product, age cohort, type of disease, mode of administration, applications in invasive and non-invasive conditions, and the end-user setting.

The product-based segmentation distinguishes between pharmaceuticals and vaccines. In the pharmaceutical segment, traditional drug therapies remain integral to immediate infection control, while the vaccine segment continues to evolve with its deeper categorization into conjugate vaccines and polysaccharide vaccines. These vaccine types offer distinct immunogenic profiles, with conjugate vaccines providing a more robust immune response in young children compared to traditional formulations.

When examining the market through the lens of age groups, the primary segments under review include infants and toddlers. This distinction is essential, as immunological maturity and the susceptibility to infections vary significantly between these young cohorts, thereby informing tailored therapeutic regimens.

Considering the disease typology, the therapeutic market is studied with reference to bacterial pneumonia, mycoplasma pneumonia, and viral pneumonia. Each of these clinical presentations demands a unique treatment pathway. Bacterial pneumonia, often more severe in its progression, necessitates aggressive and timely intervention, whereas mycoplasma and viral pneumonia may require alternative management strategies including supportive care and specific antiviral regimens.

Another crucial dimension is the mode of administration. Treatment modalities encompass several options including intramuscular, intranasal, intravenous, and oral routes. Each of these methods presents its own set of benefits and limitations, influencing both the speed of drug delivery and patient compliance. Intramuscular injections often deliver rapid systemic effects, while the ease of oral administration supports adherence to treatment protocols in outpatient settings.

Therapeutic applications further segment the market into treatments for invasive pneumococcal diseases and non-invasive pneumococcal diseases. The former includes serious conditions like bacteremia and meningitis, where swift and potent intervention is critical. Conversely, non-invasive conditions such as otitis media and sinusitis, though less severe, still require careful management to prevent complications and promote quality of life.

The setting in which treatment is rendered also provides a layer of segmentation. End-users range from clinics and hospitals to homecare settings, reflecting the varied contexts in which pediatric care is administered and the diverse economic dynamics influencing therapeutic access.

Collectively, these segmented insights underscore a market that is multifaceted and dynamic. Understanding these dimensions allows stakeholders to target specific needs within the pediatric population, ensuring that therapeutic protocols are not only effective but also tailored to meet the practical realities of both clinical and homecare environments.

Based on Product, market is studied across Drug and Vaccine. The Vaccine is further studied across Conjugate Vaccine and Polysaccharide Vaccine.

Based on Age Group, market is studied across Infants and Toddlers.

Based on Disease Type, market is studied across Bacterial Pneumonia, Mycoplasma Pneumonia, and Viral Pneumonia.

Based on Mode of Administration, market is studied across Intramuscular, Intranasal, Intravenous, and Oral.

Based on Therapeutic Applications, market is studied across Invasive Pneumococcal Diseases and Non-Invasive Pneumococcal Diseases. The Invasive Pneumococcal Diseases is further studied across Bacteremia and Meningitis. The Non-Invasive Pneumococcal Diseases is further studied across Otitis Media and Sinusitis.

Based on End-User, market is studied across Clinics, Homecare Settings, and Hospitals.

Key Regional Insights on Global Pediatric Pneumococcal Therapeutics Trends

Analyzing regional trends in pediatric pneumococcal therapeutics reveals unique market dynamics and growth opportunities that are shaped by local healthcare infrastructures, regulatory environments, and epidemiological profiles. The market's global evolution can be distilled into insights pertinent to regions such as the Americas, Europe including the Middle East and Africa, and Asia-Pacific.

In the Americas, robust healthcare systems and substantial investments in vaccine research and pharmaceutical innovations have driven significant advancements. Countries with well-established immunization programs have seen marked reductions in pneumococcal disease prevalence, which further spurs demand for novel therapeutic solutions that optimize treatment protocols and reduce the reliance on antibiotics. The increased focus on surveillance and early intervention in these regions is also shaping market strategies and fostering collaborations aimed at expanding pediatric care.

The region encompassing Europe, the Middle East, and Africa exhibits a complex tapestry of challenges and opportunities. European countries typically benefit from high technological readiness and stringent regulatory oversight, which collectively enhance the quality and safety of new therapeutics. In contrast, parts of the Middle East and Africa are experiencing rapid demographic changes and evolving healthcare frameworks, which have created a fertile ground for introducing innovative and adaptable treatment policies. Investments in infrastructure and cross-border healthcare initiatives are broadening access to both vaccines and drug therapies, thereby driving market growth even in resource-limited settings.

Across the Asia-Pacific region, the dynamics of pediatric healthcare are influenced by a combination of high population density, varying levels of economic development, and diverse public health policies. Asia-Pacific markets have witnessed increased domestic production of vaccines and a surge in research collaborations that aim to tailor treatments to local disease profiles. In addition to the rapid urbanization and rising disposable incomes in many countries within this region, there is an ever-growing emphasis on the integration of digital healthcare solutions that facilitate timely diagnosis and efficient treatment delivery.

These regional insights highlight the importance of a localized approach when designing and deploying pediatric pneumococcal therapeutics. Strategic market entrants and incumbents alike must adapt their offerings to the specific regulatory and economic contours of each region, ensuring that innovations developed in one part of the world can be successfully transposed to meet the needs of diverse patient populations globally.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape and Key Companies in the Therapeutics Market

The competitive environment within pediatric pneumococcal therapeutics is populated by a diverse array of companies, each contributing uniquely to the market dynamics. A thorough competitive analysis reveals that the landscape is characterized by both long-established pharmaceutical giants and innovative biotechnological firms. Prominent companies driving this sector include AbbVie Inc., Astellas Pharma Inc., and AstraZeneca PLC, whose extensive research and development portfolios have enabled them to stay at the forefront of therapeutic innovation.

In addition, companies such as Aurobindo Pharma Limited and Baxter International Inc. have demonstrated strong capabilities in scaling production while ensuring the availability of high-quality drug interventions. Bharat Biotech International Limited and Biocon Limited have also made significant contributions, particularly through their breakthroughs in vaccine development, which have enabled more effective preventative measures against pneumococcal infections.

Biotech disruptors like BioNTech SE and CanSino Biologics Inc. are emerging with novel approaches and agile development cycles, further intensifying competition in the vaccine segment. The presence of well-established entities like CSL Limited, along with firms such as Daiichi Sankyo Company, Limited, and Dr. Reddy's Laboratories Ltd., adds to the market's strategic depth.

Notable players such as Eli Lilly and Company, GlaxoSmithKline plc, and Glenmark Pharmaceuticals bring decades-long expertise in drug formulations and patient care innovations. The landscape is further enriched by global powerhouses like Hoffmann-La Roche AG, Johnson & Johnson, and Lupin Limited, whose focus on ensuring safety and efficacy continues to shape therapeutic trends.

Additional major contributors include Merck & Co., Inc., Moderna, Inc., Novartis AG, and Novavax, Inc., each investing heavily in research that expands the scientific understanding of immune responses in children. Entities like Panacea Biotec Ltd., Pfizer Inc., and Sanofi S.A. have maintained a robust presence in both the drug and vaccine sectors, supported by extensive clinical networks and advanced manufacturing capabilities.

The competitive scene is rounded out by influential firms such as Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Cadila, all of which continue to push the envelope in therapeutic innovations.

Overall, the industry is marked by high levels of competition, with each company leveraging its unique strengths to cater to a broad spectrum of pediatric healthcare needs. Their combined efforts are not only enhancing the quality of care but are also fostering an environment ripe for further scientific exploration and market expansion.

The report delves into recent significant developments in the Pediatrics Pneumococcal Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Bharat Biotech International Limited, Biocon Limited, BioNTech SE, CanSino Biologics Inc., CSL Limited, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Hoffmann-La Roche AG, Johnson & Johnson, Lupin Limited, Merck & Co., Inc., Moderna, Inc., Novartis AG, Novavax, Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Cadila. Actionable Recommendations for Industry Leaders in Pediatric Therapeutics

Industry leaders looking to capitalize on the evolving landscape of pediatric pneumococcal therapeutics must adopt a range of strategic actions to secure a competitive edge and ensure sustainable growth. One of the primary recommendations is to invest robustly in research and development initiatives that target both drug and vaccine innovations. Continuous investment in R&D not only accelerates the discovery of novel therapeutic agents but also enhances the refinement of existing products to address emerging resistance patterns and changing epidemiological trends.

Another key recommendation is to foster strategic partnerships that span across academia, biotechnology firms, and clinical institutions. Collaboration facilitates the pooling of expertise, resources, and technological innovation, thereby expediting the development cycle for new products. In a market where time-to-market can be a critical factor, integrated partnerships enable quicker adaptation to regulatory changes and swift dissemination of breakthroughs.

Industry leaders should also focus on enhancing their digital infrastructure. The integration of data analytics, real-time patient monitoring, and advanced diagnostic tools can not only fine-tune treatment protocols but also drive personalized medicine initiatives that cater to the distinctive needs of infants and toddlers. Embracing digital technologies helps ensure that therapeutic solutions remain patient-centric, efficient, and adaptive to real-world challenges.

Furthermore, expanding market outreach in emerging economies presents an untapped opportunity. A geographic focus on regions with evolving healthcare systems - where demand is rising due to increasing awareness and enhanced healthcare funding - can lead to substantial market penetration and revenue growth. By tailoring product portfolios to meet the specific needs identified in varying regional contexts, companies can optimize their market strategies and gain a competitive advantage.

Additionally, regulatory compliance and patient safety must remain at the forefront of strategic operations. Investing in stringent quality control measures and comprehensive clinical trials not only reinforces trust among healthcare providers but also mitigates risks associated with adverse therapeutic effects. In an industry that is under intense scrutiny, adherence to high safety standards and transparent communication with regulatory bodies are critical to sustaining market confidence.

Finally, fostering market education is essential. By developing informative platforms and outreach programs, industry incumbents can better communicate the benefits and innovative nature of new therapeutic approaches, thereby driving adoption among physicians and healthcare practitioners. These educational initiatives should be supported by compelling data and clearly articulated best practices to ensure that advancements in treatments are effectively disseminated across the healthcare continuum.

Adopting these actionable recommendations will equip industry leaders with the insights and tools necessary to navigate the complexities of the pediatric pneumococcal therapeutics market, ensuring a proactive response to both current and future challenges.

Conclusion: Shaping the Future of Pediatric Therapeutics

The evolution of pediatric pneumococcal therapeutics represents a transformative journey marked by innovative breakthroughs, strategic realignments, and a relentless pursuit of improved clinical outcomes. Analysis of the therapeutic landscape has underlined a dynamic interplay between groundbreaking drug developments and the sophisticated evolution of vaccine technologies. This confluence of advanced research, enhanced digital infrastructure, and strategic market segmentation has set the stage for a comprehensive rethinking of pediatric healthcare solutions.

The discussion provided an expansive view of the key areas shaping the market: from the detailed segmentation that distinguishes treatment modalities, age-specific considerations, and disease profiles, to the regional insights that reveal distinctive growth opportunities across the Americas, Europe including the Middle East and Africa, and the Asia-Pacific region. Moreover, competition among leading companies-ranging from established giants to innovative disruptors-illustrates the robust activity and potential for sustained momentum in the market.

In light of these factors, stakeholders can draw significant learnings regarding both the challenges and opportunities that are intrinsic to the field. The insights offered in this analysis support a strategic recalibration that emphasizes personalized medicine, the synergy of cross-sector partnerships, and a dedicated focus on regional diversity in healthcare needs. As the industry continues to evolve, the drive towards innovative, patient-centric solutions will remain a cornerstone of effective therapeutic strategies for pediatric populations worldwide.

Ultimately, the advancements in pediatric pneumococcal therapeutics provide not only a window into the future of treatment and prevention but also a roadmap for how industries can harmonize clinical innovations with market realities. This confluence of strategy and science underscores the promise of a healthier future for children, where precision medicine and proactive interventions stand as bulwarks against the challenges of infectious diseases.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness about pneumococcal diseases among parents and healthcare providers
      • 5.1.1.2. Rising adoption of combination vaccines amplifies pediatric pneumococcal drugs
      • 5.1.1.3. Government initiatives and policies promoting vaccination and preventative healthcare
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with R&D limit the entry of new competitors
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing age-specific formulations to better cater to different pediatric age groups
      • 5.1.3.2. Investing in telemedicine technology to expand reach and improve patient outcomes
    • 5.1.4. Challenges
      • 5.1.4.1. Meeting the growing ethical concerns and transparency demands regarding drug trials in children
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing adoption of conjugate vaccines due to their proven efficacy in infants
    • 5.2.2. Therapeutic Applications: Expanding the application of pediatrics pneumococcal therapeutics in invasive pneumococcal diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pediatrics Pneumococcal Therapeutics Market, by Product

  • 6.1. Introduction
  • 6.2. Drug
  • 6.3. Vaccine
    • 6.3.1. Conjugate Vaccine
    • 6.3.2. Polysaccharide Vaccine

7. Pediatrics Pneumococcal Therapeutics Market, by Age Group

  • 7.1. Introduction
  • 7.2. Infants
  • 7.3. Toddlers

8. Pediatrics Pneumococcal Therapeutics Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Bacterial Pneumonia
  • 8.3. Mycoplasma Pneumonia
  • 8.4. Viral Pneumonia

9. Pediatrics Pneumococcal Therapeutics Market, by Mode of Administration

  • 9.1. Introduction
  • 9.2. Intramuscular
  • 9.3. Intranasal
  • 9.4. Intravenous
  • 9.5. Oral

10. Pediatrics Pneumococcal Therapeutics Market, by Therapeutic Applications

  • 10.1. Introduction
  • 10.2. Invasive Pneumococcal Diseases
    • 10.2.1. Bacteremia
    • 10.2.2. Meningitis
  • 10.3. Non-Invasive Pneumococcal Diseases
    • 10.3.1. Otitis Media
    • 10.3.2. Sinusitis

11. Pediatrics Pneumococcal Therapeutics Market, by End-User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Homecare Settings
  • 11.4. Hospitals

12. Americas Pediatrics Pneumococcal Therapeutics Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Pediatrics Pneumococcal Therapeutics Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Pediatrics Pneumococcal Therapeutics Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Sanofi and SK bioscience advance phase 3 PCV21 program to enhance global pediatric pneumococcal protection
    • 15.3.2. Hong Kong Department of Health approved Pfizer's 20-valent Pneumococcal Conjugate Vaccine
    • 15.3.3. Abbott India launched PneumoShield 14, a new pneumococcal conjugate vaccine
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca PLC
  • 4. Aurobindo Pharma Limited
  • 5. Baxter International Inc.
  • 6. Bharat Biotech International Limited
  • 7. Biocon Limited
  • 8. BioNTech SE
  • 9. CanSino Biologics Inc.
  • 10. CSL Limited
  • 11. Daiichi Sankyo Company, Limited
  • 12. Dr. Reddy's Laboratories Ltd.
  • 13. Eli Lilly and Company
  • 14. GlaxoSmithKline plc
  • 15. Glenmark Pharmaceuticals
  • 16. Hoffmann-La Roche AG
  • 17. Johnson & Johnson
  • 18. Lupin Limited
  • 19. Merck & Co., Inc.
  • 20. Moderna, Inc.
  • 21. Novartis AG
  • 22. Novavax, Inc.
  • 23. Panacea Biotec Ltd.
  • 24. Pfizer Inc.
  • 25. Sanofi S.A.
  • 26. Serum Institute of India Pvt. Ltd.
  • 27. Sinovac Biotech Ltd.
  • 28. Takeda Pharmaceutical Company Limited
  • 29. Teva Pharmaceutical Industries Ltd.
  • 30. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY TODDLERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY BACTERIAL PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MYCOPLASMA PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VIRAL PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY BACTEREMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY OTITIS MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY SINUSITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 222. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 249. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY